Protective effect of rosuvastatin on acute kidney Injury in the patients after coronary artery bypass grafting

Objective To investigate the prevention of acute kidney injury (AKI) by earlier application of rosuvastatin in patients after coronary artery bypass grafting (CABG). Methods A total of 200 patients with CABG were enrolled from May 2013 to April 2017. According to whether rosuvastatin were used routinely before operation or not, all patients were divided into the trial group (n = 136) and the control group (n = 64). Demographics, and clinical data were collected before and after CABG. The renal function markers including blood urea nitrogen (BUN), serum creatinine (sCr), eridogenous creatinine clearance rate (GFR) , emergence of AKI of two groups were documented and compared. Enumeration data were analyzed with x2 test, measurement data were analyzed with t test, and P <0. 05 was considered to be significant. Results There were no differences in sCr (: = - 1. 156, P >0. 05) but differences in BUN and eGFR ( t = - 2. 915, 3. 690, respectively, P <0. 05) before operation between two groups. After operation, the BUN was decreased (t = 2. 486, P <0. 05) compared with that of pre-operation in the trial group, but there were no significant difference in sCr and eGFR (t = - 1. 877, -0. 752, respectively, p> 0. 05). The BUN and sCr were increased (t = -3. 792, -5. 027, respectively, P <0. 05) after operation compared with that of pre-operation in the control group, while the eGFR was decreased (t = 5. 540, P < 0. 05) . Compared with the control group, BUN, sCr and the incidence of AKI were significantly decreased in the trial group ( t/x2 =5.759, 4. 1.96, 15. 506, respectively, P <0.05), while the eGFR was increased Ct = -6. 215, P <0. 05). Conclusions Earlier application of rosuvastatin before CABG can effectively protect renal function and reduce the incidence of AKI.